Adjuvant and neoadjuvant chemotherapy in the treatment of adrenocortical carcinoma
(ACC) is limited by few existing trials, most of which are retrospective. The drug mitotane has …

Up to 30% of adrenocortical carcinoma (ACC) patients have metastasised disease upon
initial presentation, and systemic treatments currently fail to sufficiently improve survival …

Introduction Historically, stage IV adrenocortical carcinoma (mACC) has a poor prognosis
with a median overall survival (OS) of only 5 months. Based on the FIRM-ACT trial published …

Adrenocortical carcinoma (ACC) is a rare but very aggressive malignancy of the endocrine
system with specific biology characterized frequently by hormonal activity and high …

Despite the development of new therapeutic strategies, cancer remains one of the leading
causes of mortality worldwide. One of the current major challenges is the resistance of …

Treatment of adrenocortical carcinoma: oncological and endoc... : Current Opinion in
Urology Treatment of adrenocortical carcinoma: oncological and endocrine outcomes …

Адренокортикальный рак-редко встречаемая опухоль, происходящая из кортикальных
клеток надпочечников, характеризующаяся агрессивным потенциалом, быстро …

Background Adrenocortical carcinoma (ACC) is a rare malignancy occurring in the adrenal
cortex characterized by its low incidence rate, aggressive tumor behavior with high …

Response to Letter RE: Impact of EDP-M on survival of patients with metastatic adrenocortical
carcinoma: A population-based study Response to Letter RE: Impact of EDP-M on survival of …

Metastatic hormone-producing tumors have characteristics of both tumors and endocrine
disorders with many time-series parameters. Therefore, making treatment decisions is often …